Skip to main content

Table 2 Included studies and the evaluation methods employed, together with major outcomes for each method

From: Systemic administration of strontium ranelate to enhance the osseointegration of implants: systematic review of animal studies

Study   Tests and overall results
Bone mineral density Histomorphometric Biomechanical MicroCT Nanoindentation Serum analysis
Maïmoun et al. 2010 [29] _ _ SRAN > C SRAN > C
(trabecular bone microarchitecture and BIC)
SRAN > C
(elastic modulus, tissue hardness, and working energy)
_
Li et al. 2010 [32] _ _ OVX + SRH=CS > OVX + SRANL > OVX OVX + SRANH > CS > OVX + SRANL > OVX _ _
Li et al. 2012 [33] _ OVX + SRAN > OVX
(BIC and BA)
OVX + SRAN > OVX OVX + SRAN > OVX _ OVX + SRAN > OVX
(OCN)
OVX + SRAN < OVX
(TRAP)
Linderbäck et al. 2012 [30] BPA > SRAN=C
(4 and 8 weeks)
BPA > SRAN=C
(4 and 8 weeks)
BPA > SRAN=C
(4 and 8 weeks)
BPA > SRAN=C
(around implant)
BPA > SRAN > C
(growth plate)
_ _
Chen et al. 2013 [31] BPZ = CS > BPA = SRAN > OVX BPZ = CS > BPA = SRAN > OVX BPZ = CS > BPA = SRAN > OVX _ _ _
  1. C S sham operation as a control positive group, C control, SRAN strontium ranelate, OVX ovariectomy, SRANL strontium ranelate low dose, SR H strontium ranelate high dose, BP bisphosphonate, BP A alendronate, BP Z zolendronate, BIC bone contact implant, BA bone area, OCN osteocalcin, TRAP tartrate-resistant acid phosphatase